LLY Stock Hits All-Time High After Goldman Sachs Raises Price Target Ahead Of Q3 Earnings

Eli Lilly (LLY) shares rose 4.36% to $1,294.36 on October 20. The gain followed a collaboration with METiS, which includes a $1.1 billion milestone potential. The upfront payment is undisclosed but in the low double-digit millions. Most payments depend on future progress. Lilly's stock is 18.12% below the GF Value estimate of $1,580.

Eli Lilly's stock rose 4.36% to $1,294.36 on October 20 following a collaboration with METiS. The deal includes a $1.1 billion milestone potential, with upfront payment in the low double-digit millions. The partnership focuses on AI-driven drug delivery, but is still in the research-and-discovery stage. Lilly's stock is 18.12% below its GF Value estimate of $1,580.

Eli Lilly (LLY) stock rose 4% to $1,295.58 after a European regulatory committee recommended approval for its obesity pill, Foundayo. Amgen (AMGN) and Novo Nordisk (NVO) stocks also gained 2%. Foundayo's approval would make it the second oral drug of its class in the EU, with a broader label than Novo Nordisk's Wegovy. The iShares Biotechnology ETF (IBB) rose 2%.

Metis TechBio, a Chinese AI-driven drug delivery startup, has partnered with Eli Lilly in a deal worth up to $1.1 billion. The collaboration focuses on developing novel lipid nanoparticle-based delivery solutions for targeted therapies. Metis will receive an upfront payment and potential milestone payments, plus royalties on future sales.

Eli Lilly shares rose 4.6% to a record high after Goldman Sachs raised its price target to $1,413 and maintained a Buy rating. BofA also increased its target to $1,397. Analysts expect revenue of $88.5 billion this year, with Q3 results due on October 29.

Eli Lilly (LLY) stock rose 3.7% after positive Phase 3 trial results for Omvoh in pediatric ulcerative colitis and a $1.1B AI partnership with JT Therapeutics. Cantor Fitzgerald raised its price target to $1,440. LLY traded at $1,286.61, near its 52-week high of $1,292.65.